Frontiers in endocrinology · 2025
Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen I-Wen, Lin Cheng-Wei, Lin Chia-Ni, Chen Szu-Tah
Аннотация
BACKGROUND: To investigate the value of serum adropin in predicting chronic kidney disease (CKD) progression in subjects with type 2 diabetes (T2D).
MATERIALS AND METHODS: Serum adropin levels were measured in normal control and T2D patients with various stage of CKD. CKD progression was defined as ≥ 30% decline from the baseline estimated glomerular filtration rate. Logistic regression analysis was applied to assess the association between adropin levels and CKD progression.
RESULTS: The study included 58 subjects with T2D (18 early CKD and 40 advanced CKD) and 9 subjects without diabetes (control). Subjects with T2D had significantly higher adropin levels than controls (6393.10 ± 1611.84 vs. 3470.30 ± 1284.41 pg/ml; P < 0.001). Meanwhile, T2D patients with advanced CKD had higher adropin levels than those with early CKD (6848.89 ± 1287.04 vs. 5380.25 ± 1826.44 pg/ml; P = 0.003). Among T2D patients, subjects experienced CKD progression had higher adropin levels than those without (7520.15 ± 843.21 vs. 6151.16 ± 1661.61 pg/mL, P =0.003). Thus, adropin predicts CKD progression in T2D patients with 86% sensitivity and 70% specificity at 6872.24 pg/ml cutoff value. The association with CKD progression was still significant after adjusting for age, gender and body mass index (adjusted odds ratio = 27.188, 95% confidence interval 1.415-522.527, P =0.029).
CONCLUSIONS: The above findings suggest that serum adropin could be applied as a potential biomarker for predicting CKD progression in subjects with T2D. Further research is needed to validate these results and explore the underlying mechanisms.
MATERIALS AND METHODS: Serum adropin levels were measured in normal control and T2D patients with various stage of CKD. CKD progression was defined as ≥ 30% decline from the baseline estimated glomerular filtration rate. Logistic regression analysis was applied to assess the association between adropin levels and CKD progression.
RESULTS: The study included 58 subjects with T2D (18 early CKD and 40 advanced CKD) and 9 subjects without diabetes (control). Subjects with T2D had significantly higher adropin levels than controls (6393.10 ± 1611.84 vs. 3470.30 ± 1284.41 pg/ml; P < 0.001). Meanwhile, T2D patients with advanced CKD had higher adropin levels than those with early CKD (6848.89 ± 1287.04 vs. 5380.25 ± 1826.44 pg/ml; P = 0.003). Among T2D patients, subjects experienced CKD progression had higher adropin levels than those without (7520.15 ± 843.21 vs. 6151.16 ± 1661.61 pg/mL, P =0.003). Thus, adropin predicts CKD progression in T2D patients with 86% sensitivity and 70% specificity at 6872.24 pg/ml cutoff value. The association with CKD progression was still significant after adjusting for age, gender and body mass index (adjusted odds ratio = 27.188, 95% confidence interval 1.415-522.527, P =0.029).
CONCLUSIONS: The above findings suggest that serum adropin could be applied as a potential biomarker for predicting CKD progression in subjects with T2D. Further research is needed to validate these results and explore the underlying mechanisms.